|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
AU4025193A
(en)
|
1992-04-08 |
1993-11-18 |
Cetus Oncology Corporation |
Humanized C-erbB-2 specific antibodies
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
KR20110008112A
(ko)
|
1999-08-27 |
2011-01-25 |
제넨테크, 인크. |
항-ＥｒｂＢ2 항체 투여 치료 방법
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
ES2248127T3
(es)
|
1999-10-04 |
2006-03-16 |
Medicago Inc. |
Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
|
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
|
RU2420537C2
(ru)
|
2001-01-17 |
2011-06-10 |
Трабьон Фармасьютикалз Инк. |
Слитые белки связывающий домен-иммуноглобулин
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
WO2004032961A1
(en)
|
2002-10-10 |
2004-04-22 |
Merck Patent Gmbh |
Bispecific anti-erb-b antibodies and their use in tumor therapy
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
NZ579482A
(en)
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
CN102580084B
(zh)
*
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
WO2008031531A1
(en)
*
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Tumor therapy with a combination of anti-her2 antibodies
|
|
EP2650311A3
(en)
|
2007-11-27 |
2014-06-04 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
KR101658247B1
(ko)
|
2008-01-03 |
2016-09-22 |
더 스크립스 리서치 인스티튜트 |
모듈 인식 도메인을 통한 항체 표적화
|
|
JP6157046B2
(ja)
|
2008-01-07 |
2017-07-05 |
アムジェン インコーポレイテッド |
静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
|
MX340971B
(es)
|
2009-11-23 |
2016-08-02 |
Amgen Inc * |
Fragmento cristalizable (fc) de anticuerpo monomerico.
|
|
US8961967B2
(en)
|
2009-11-30 |
2015-02-24 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
TW201138821A
(en)
*
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
WO2011135040A1
(en)
|
2010-04-30 |
2011-11-03 |
F. Hoffmann-La Roche Ag |
Fluorescent antibody fusion protein, its production and use
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
ES2758994T3
(es)
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
BR112013023918A2
(pt)
*
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
US20130216523A1
(en)
|
2011-03-31 |
2013-08-22 |
Laboratory Corporation Of America Holdings |
Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
|
|
CN103796678B
(zh)
*
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
|
RU2654567C2
(ru)
*
|
2011-10-11 |
2018-05-21 |
Дженентек, Инк. |
Улучшенная сборка биспецифических антител
|
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
|
JP6325463B2
(ja)
|
2012-03-16 |
2018-05-16 |
コヴァジェン アクチェン ゲゼルシャフト |
抗腫瘍活性を有する新規結合分子
|
|
KR20150008171A
(ko)
|
2012-05-10 |
2015-01-21 |
자임워크스 인코포레이티드 |
단일군 일가 항체 구조물 및 그의 용도
|
|
AU2013258834B2
(en)
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
WO2014060365A1
(en)
|
2012-10-15 |
2014-04-24 |
Universität Zürich Prorektorat Mnw |
Bispecific her2 ligands for cancer therapy
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
KR102332303B1
(ko)
|
2013-05-31 |
2021-11-26 |
자임워크스 인코포레이티드 |
감소되거나 침묵화된 효과기 기능을 갖는 이종다량체
|
|
AU2014357292B2
(en)
*
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
EP3083696B1
(en)
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
ES3057390T3
(en)
|
2015-05-13 |
2026-03-02 |
Zymeworks Bc Inc |
Antigen-binding constructs targeting her2
|
|
IL277049B2
(en)
*
|
2018-03-13 |
2024-02-01 |
Zymeworks Bc Inc |
Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
|